Which PDE5 inhibitor is the most effective in the treatment of erectile dysfunction in men with spinal cord injury? A systematic review and network meta‐analysis

Author:

Tienforti Daniele1,Felzani Giorgio2,Di Pasquale Alfonso Boris3,Barbonetti Arcangelo1ORCID

Affiliation:

1. Andrology Unit Department of Clinical Medicine Life, Health and Environmental Sciences University of L'Aquila L'Aquila Italy

2. Spinal Unit San Raffaele Sulmona Institute Sulmona Italy

3. Department of Urology Urology Unit, ASL 1 Abruzzo “S. Salvatore” Hospital L'Aquila Italy

Abstract

AbstractBackgroundPhosphodiesterase 5 inhibitors (PDE5i) are the first‐line drugs for erectile dysfunction (ED) but differences among available molecules should drive therapy personalization. Choosing one PDE5i over another is a challenge in men with spinal cord injury (SCI), as the evidence of efficacy for each molecule is derived from few studies and comparative “head‐to‐head” trials are lacking.ObjectiveTo assess the efficacy of the different PDE5i for SCI‐related ED with a network meta‐analysis (NMA) approach.Materials and methodsDatabases from PubMed, Web of Science, Scopus, and Cochrane Library were checked for randomized controlled trials (RCTs) comparing any PDE5i to each other or placebo in men with traumatic SCI lasting ≥6 months. Data were incorporated in a random‐effect NMA, where treatments’ efficacy was ranked using the surface under the cumulative ranking curve (SUCRA).ResultsThe 10 RCTs included provided information about 1,492 men with ED due to traumatic SCI. Intervention arms included sildenafil, tadalafil, and/or vardenafil. Overall, at the pairwise meta‐analysis, PDE5i were four times more effective than placebo in improving erectile function (risk ratio: 4.13, 95% CI: 2.76, 6.19). The comparative analysis from NMA revealed that tadalafil was associated with the highest SUCRA value (81%), followed by vardenafil (68%) and sildenafil (49%).Discussion and conclusionWithin the grading of comparison network, tadalafil appeared to be the best PDE5i in the treatment of SCI‐related ED. Further focused studies are warranted to confirm these findings and define optimal doses and duration of therapy.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3